MTOR and cancer: The collective prevalence of mTOR pathway mutations is appreciable among the common cancers (2.8% on average), including many cancers in which rapalogs are rarely used (e.g. lung adenocarcinoma, lung squamous cell carcinoma, melanoma, pancreatic adenocarcinoma, uterine carcinoma all have a prevalence > 1%) — highlighting the possibility of additional groups of patients who might benefit from these drugs.